Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30574489 | 1.00 | CYP2C19 (0.44) | CYP2C19CYP2C9HTTKMT2AALDH1A1 | |
| SCHEMBL9664845 | 0.87 | KMT2A (0.50) | KMT2AALDH1A1CYP3A4 | |
| SCHEMBL649031 | 0.80 | CYP2C19 (0.46) | CYP2C19CYP2C9HTTKMT2AALDH1A1 | |
| SCHEMBL31383801 | 0.80 | CYP2C19 (0.49) | CYP2C19CYP2C9HTTKMT2AALDH1A1 | |
| SCHEMBL1345452 | 0.80 | CYP2C19 (0.49) | CYP2C19CYP2C9HTTKMT2AALDH1A1 | |
| SCHEMBL8568940 | 0.80 | ALDH1A1 (0.47) | KMT2AALDH1A1POLBCYP3A4 | |
| SCHEMBL30078420 | 0.80 | CYP2C19 (0.46) | CYP2C19CYP2C9HTTKMT2AALDH1A1 | |
| SCHEMBL7976422 | 0.80 | CA1 (0.47) | HTTKMT2AALDH1A1POLB | |
| SCHEMBL9126501 | 0.80 | CYP2C19 (0.46) | CYP2C19CYP2C9HTTKMT2AALDH1A1 | |
| SCHEMBL27808763 | 0.79 | KMT2A (0.41) | CYP2C19CYP2C9HTTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999731-B2 | EGFR dimer disruptors and use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2024-05-30 | — | — | US | disclosed |
| EP-4288412-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | Rappta Therapeutics Oy (FI) | 2023-12-13 | — | — | EP | disclosed |
| US-20220340572-A1 | EGFR DIMER DISRUPTORS AND USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-10-27 | — | — | US | disclosed |
| WO-2022167866-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2022-08-11 | — | — | WO | disclosed |
| US-11358965-B2 | EGFR dimer disruptors and use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3755323-A1 | EGFR DIMER DISRUPTORS AND USE OF THE SAME | The Regents Of The University Of Michigan (US) | 2020-12-30 | — | — | EP | disclosed |
| US-20200377503-A1 | EGFR DIMER DISRUPTORS AND USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2020-12-03 | — | — | US | disclosed |
| CN-111886009-A | EGFR dimer disruptors and uses thereof | 密歇根大学董事会 | 2020-11-03 | — | — | CN | disclosed |
| WO-2019165358-A1 | EGFR DIMER DISRUPTORS AND USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358965-B2 | EGFR dimer disruptors and use of the same | EGFR, ERBB2, ERBB4 | CYP2C19 4266/4885CYP2C9 4164/4885HTT 3104/4885 |
| US-20220340572-A1 | EGFR DIMER DISRUPTORS AND USE OF THE SAME | EGFR, ERBB2, ERBB4 | CYP2C19 4266/4885CYP2C9 4164/4885HTT 3104/4885 |
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | PPM1A, PPP2CA, PPP3CA | CYP2C19 4761/4885CYP2C9 4632/4885HTT 2274/4885 |
| US-11999731-B2 | EGFR dimer disruptors and use of the same | EGFR, ERBB2, ERBB4 | CYP2C19 4266/4885CYP2C9 4164/4885HTT 3104/4885 |
| US-20200377503-A1 | EGFR DIMER DISRUPTORS AND USE OF THE SAME | EGFR, ERBB2, ERBB4 | CYP2C19 4266/4885CYP2C9 4164/4885HTT 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.